New pill shows promise against tough breast cancer
NCT ID NCT04505826
First seen May 15, 2026 · Last updated May 18, 2026 · Updated 1 time
Summary
This study tested a new daily pill, OP-1250, in 153 adults with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. The goal was to find the right dose, check safety, and see if the drug can shrink tumors. Participants had already tried at least one hormone therapy before joining.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advent Health
Orlando, Florida, 32804, United States
-
Cancer Research South Australia
Adelaide, South Australia, 5000, Australia
-
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Center
Sarasota, Florida, 34232, United States
-
ICON Cancer Centre
Auchenflower, Queensland, 4066, Australia
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Macquarie University
Sydney, New South Wales, 2109, Australia
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
UCLA Hematology/Oncology
Los Angeles, California, 90404, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Miami, Sylvester Comprehensive Cancer Center
Deerfield Beach, Florida, 33442, United States
-
Westmead
Westmead, New South Wales, 2145, Australia
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.